A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury.
DeFilippis AP, Chapman AR, Mills NL, de Lemos JA, Arbab-Zadeh A, Newby LK, Morrow DA.
Circulation. 2019 Nov 12;140(20):1661-1678. doi: 10.1161/CIRCULATIONAHA.119.040631. Epub 2019 Aug 16.
Risk factors for type 1 and type 2 myocardial infarction.
Wereski R, Kimenai DM, Bularga A, Taggart C, Lowe DJ, Mills NL, Chapman AR.
Eur Heart J. 2022 Jan 13;43(2):127-135. doi: 10.1093/eurheartj/ehab581.
Digital Health Intervention in Acute Myocardial Infarction.
Marvel FA, Spaulding EM, Lee MA, Yang WE, Demo R, Ding J, Wang J, Xun H, Shah LM, Weng D, Carter J, Majmudar M, Elgin E, Sheidy J, McLin R, Flowers J, Vilarino V, Lumelsky DN, Bhardwaj V, Padula WV, Shan R, Huynh PP, Wongvibulsin S, Leung C, Allen JK, Martin SS.
Circ Cardiovasc Qual Outcomes. 2021 Jul;14(7):e007741. doi: 10.1161/CIRCOUTCOMES.121.007741. Epub 2021 Jul 15.
Defining and managing patients with non-ST-elevation myocardial infarction: Sorting through type 1 vs other types.
Cohen M, Visveswaran G.
Clin Cardiol. 2020 Mar;43(3):242-250. doi: 10.1002/clc.23308. Epub 2020 Jan 10.
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.
Keeley EC, Boura JA, Grines CL.
Lancet. 2003 Jan 4;361(9351):13-20. doi: 10.1016/S0140-6736(03)12113-7.
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.
Harrington J, Udell JA, Jones WS, Anker SD, Bhatt DL, Petrie MC, Vedin O, Sumin M, Zwiener I, Hernandez AF, Butler J.
Am Heart J. 2022 Nov;253:86-98. doi: 10.1016/j.ahj.2022.05.010. Epub 2022 May 17.
Secretome Analysis of Cardiomyocytes Identifies PCSK6 (Proprotein Convertase Subtilisin/Kexin Type 6) as a Novel Player in Cardiac Remodeling After Myocardial Infarction.
Kuhn TC, Knobel J, Burkert-Rettenmaier S, Li X, Meyer IS, Jungmann A, Sicklinger F, Backs J, Lasitschka F, Müller OJ, Katus HA, Krijgsveld J, Leuschner F.
Circulation. 2020 May 19;141(20):1628-1644. doi: 10.1161/CIRCULATIONAHA.119.044914. Epub 2020 Feb 26.
Outcomes of Acute Myocardial Infarction in Female Patients With Type 1 Diabetes Mellitus.
Santana JC, Dangl M, Albosta M, Colombo R.
Am J Cardiol. 2023 Nov 1;206:12-13. doi: 10.1016/j.amjcard.2023.08.041. Epub 2023 Sep 5.
Timing of SGLT2i initiation after acute myocardial infarction.
von Lewinski D, Kolesnik E, Aziz F, Benedikt M, Tripolt NJ, Wallner M, Pferschy PN, von Lewinski F, Schwegel N, Holman RR, Oulhaj A, Moertl D, Siller-Matula J, Sourij H.
Cardiovasc Diabetol. 2023 Sep 30;22(1):269. doi: 10.1186/s12933-023-02000-5.
High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction.
Chapman AR, Adamson PD, Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Berry C, Findlay I, Cruikshank A, Reid A, Gray A, Collinson PO, Apple F, McAllister DA, Maguire D, Fox KAA, Vallejos CA, Keerie C, Weir CJ, Newby DE, Mills NL; High-STEACS Investigators.
Circulation. 2020 Jan 21;141(3):161-171. doi: 10.1161/CIRCULATIONAHA.119.042960. Epub 2019 Oct 7.
